Cipla Ltd. announced the incorporation of a wholly owned subsidiary, CiplaRna GmbH, in Germany on May 28, 2025, to focus on mRNA-based formulation and drug development. Cipla (EU) Limited has acquired 100% control by subscribing to 25,000 shares at EUR 1 each.